FRIDAY, Oct. 12 (HealthDay News) -- Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration -- in combination with the drug carboplatin -- to treat advanced or spreading non-small cell lung cancer among people who aren't candidates for surgery or radiation therapy, the agency said Friday.
Latest Cancer News
Abraxane was first approved in 2005 to treat breast cancer.
Abraxane is produced by Celgene Corp., based in Summit, N.J.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.
Subscribe to MedicineNet's Cancer Report Newsletter